Filing Flows

Filing Flows › Haemonetics (HAE) › Next earnings date

Haemonetics (HAE) earnings: beat the estimate

Haemonetics (HAE) reported on Nov 5, 2026 and beat the EPS estimate: $1.35 against $1.29 (+4.6%). Revenue was $358M for Q2 FY27, +9% year over year. The stock moved -5.9% on the report. It beat the EPS estimate in 100% of the quarters on record.

Last result+4.6% vs estimate
Beat rate100%

The last report

Haemonetics reported revenue of $358M for the second quarter fiscal 2027 (+9% Y/Y), net earnings $46.3M: Apheresis $205M, MedSurg $153M. How it makes money → · Every quarter →

Haemonetics: EPS against the estimate, last 5 reportsHaemonetics: EPS against the estimate, last 5 reportsEstimateReported$1.11$1.27Nov 25$1.25$1.31Feb 26$1.27$1.29May 26$1.08$1.14Aug 26$1.29$1.35Nov 26
Latest (Nov 26): Estimate $1.29, Reported $1.35.
HAE: the stock's move on each reportHAE: the stock's move on each reportNov 5, 2026-5.9%Aug 6, 2026+5.1%May 7, 2026+4.7%Feb 5, 2026-10.0%Nov 6, 2025+34.8%

Haemonetics' latest quarter

Haemonetics, Q2 FY27: revenue $358M (+9% year over year), operating margin 21.0%, net earnings $46.3M, operating cash flow $128M. The chart follows the revenue to costs, profit and cash.

Questions

Did Haemonetics beat earnings?

Haemonetics (HAE) reported on Nov 5, 2026 and beat the EPS estimate: $1.35 against $1.29 (+4.6%).

When does HAE report earnings?

The next date is not set yet.

Does Haemonetics usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.